Autoimmune Diseases  >>  DiaPep277  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DiaPep277 / Evotec, Amgen
DIA-AID, NCT00615264: Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Checkmark
Jan 2014 - Jan 2014: 
Checkmark EASD 2013
Jul 2013 - Jul 2013: EASD 2013
Checkmark ADA 2013
More
Completed
3
457
Europe, RoW
DiaPep277, Placebo
Andromeda Biotech Ltd.
Type 1 Diabetes
09/11
01/12
NCT00644501: Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes

Checkmark EASD 2013
Jul 2013 - Jul 2013: EASD 2013
Checkmark ADA 2013
Jun 2013 - Jun 2013: ADA 2013
Checkmark
More
Completed
3
43
RoW
DiaPep277
Andromeda Biotech Ltd.
Type 1 Diabetes
05/13
06/13
DIA-AID 2, NCT01898286 / 2013-002775-17: Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

Terminated
3
38
US
DiaPep277®
Andromeda Biotech Ltd.
Type 1 Diabetes
09/14
12/14
DIA-AID2, NCT01103284: Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

Checkmark P3 enrollment completion
Sep 2012 - Sep 2012: P3 enrollment completion
Completed
3
475
US, Canada, Europe, RoW
DiaPep277, Placebo
Andromeda Biotech Ltd.
Type 1 Diabetes Mellitus
10/14
10/14
NCT01460251: OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277

Terminated
3
11
RoW
DiaPep277
Rabin Medical Center
Type 1 Diabetes
12/14
02/15

Download Options